New oral drug shows promise against deadly lassa fever in west africa trial
NCT ID NCT07419373
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever, a serious viral illness common in West Africa. About 135 hospitalized adults will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin, for 10 days. The goal is to see if the new pill is safe and can reduce the virus faster than the current treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LASSA FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abubakar Tafawa Balewa University Teaching Hospital
Bauchi, Nigeria
-
Arisan Therapeutics
Carlsbad, California, 92008, United States
-
Federal Medical Centre, Owo
Owo, Ondo State, Nigeria
-
Irrua Specialist Teaching Hospital
Irrua, 310115, Nigeria
More trials for these conditions
Other studies related to the condition(s) this trial covers.